Abstract:Background & aims: Choline kinase α (CHKA) catalyzes conversion of choline to phosphocholine and can contribute to carcinogenesis. Little is known about the role of CHKA in the pathogenesis of hepatocellular carcinoma (HCC). Methods: We performed whole-exome and transcriptome sequence analyses of 9 paired HCC and non-tumor-adjacent tissues. We performed tissue chip analyses of 120 primary HCC and non-tumor-adjacent tissues from patients who received surgery in Shanghai, China from January 2006 through December 2009; 48 sets of specimens (HCC and non-tumor-adjacent tissues) were also analyzed. CHKA gene copy number was quantified and findings were validated by quantitative reverse transcription polymerase chain reaction analysis. CHKA messenger RNA and protein levels were determined by polymerase chain reaction, immunohistochemical, and immunoblot analyses. CHKA was examined in 2 hepatocyte cell lines and 7 HCC-derived cell lines, and knocked down with small interfering RNAs in 3 HCC cell lines. Cells were analyzed in proliferation, wound healing, migration, and invasion assays. Cells were injected into tail veins of mice and tumor growth and metastasis were quantified. Immunoprecipitation and immunofluorescence assays were conducted to determine interactions between CHKA and the epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin complex 2. Results: Levels of CHKA messenger RNA were frequently increased in HCC tissues compared with nontumor tissues; increased expression was associated with amplification at the CHKA loci. Tumors that expressed high levels of CHKA had more aggressive phenotypes, and patients with these tumors had shorter survival times after surgery compared to patients whose tumors expressed low levels of CHKA. HCC cell lines that stably overexpressed CHKA had higher levels of migration and invasion than control HCC cells, and formed larger xenograft tumors with more metastases in mice compared to HCC cells that did not overexpress CHKA. CHKA was required for physical interaction between EGFR and mechanistic target of rapamycin complex 2. This complex was required for HCC cells to form metastatic xenograft tumors in mice and to become resistant to EGFR inhibitors. Conclusions: We found levels of CHKA to be increased in human HCCs compared to nontumor tissues, and increased expression to be associated with tumor aggressiveness and reduced survival times of patients. Overexpression of CHKA in HCC cell lines increased their invasiveness, resistance to EGFR inhibitors, and ability to form metastatic tumors in mice by promoting interaction of EGFR with mechanistic target of rapamycin complex 2.

CRKL Promotes Hepatocarcinoma Through Enhancing Glucose Metabolism of Cancer Cells Via Activating PI3K/Akt.

CRKL Knockdown Promotes in Vitro Proliferation, Migration and Invasion, in Vivo Tumor Malignancy and Lymph Node Metastasis of Murine Hepatocarcinoma Hca-P Cells

CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma

The E3 Ubiquitin Ligase RBCK1 Promotes The Invasion and Metastasis of Hepatocellular Carcinoma By Destroying The PPARγ/PGC1α Complex

Inhibition of GSK-3β Activity Suppresses HCC Malignant Phenotype by Inhibiting Glycolysis Via Activating AMPK/mTOR Signaling.

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer

Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation

Downregulation of CRKL Expression Can Inhibit Tumorigenesis in Colon Cancer.

PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A

PCK1 Negatively Regulates Cell Cycle Progression and Hepatoma Cell Proliferation Via the AMPK/p27Kip1 Axis

A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process

Overexpression of PIK3R1 Promotes Hepatocellular Carcinoma Progression

PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition

PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.

MLKL Promotes Hepatocarcinogenesis Through Inhibition of AMPK-mediated Autophagy

GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway

Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway

The CX3CL1/CX3CR1 Reprograms Glucose Metabolism Through HIF-1 Pathway in Pancreatic Adenocarcinoma.

Gankyrin and TIGAR Cooperatively Accelerate Glucose Metabolism Toward the PPP and TCA Cycle in Hepatocellular Carcinoma

Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression